Merck & Company Company Profile (NYSE:MRK)

About Merck & Company (NYSE:MRK)

Merck & Company logoMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:MRK
  • CUSIP: 58933Y10
  • Web:
  • Market Cap: $172.42 billion
  • Outstanding Shares: 2,727,354,000
Average Prices:
  • 50 Day Moving Avg: $64.57
  • 200 Day Moving Avg: $63.71
  • 52 Week Range: $58.29 - $66.80
  • Trailing P/E Ratio: 34.29
  • Foreward P/E Ratio: 15.20
  • P/E Growth: 2.64
Sales & Book Value:
  • Annual Revenue: $40.02 billion
  • Price / Sales: 4.31
  • Book Value: $14.47 per share
  • Price / Book: 4.37
  • Annual Dividend: $1.88
  • Dividend Yield: 2.9%
  • EBITDA: $15.45 billion
  • Net Margins: 17.14%
  • Return on Equity: 26.02%
  • Return on Assets: 11.15%
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 1.50%
  • Quick Ratio: 1.21%
  • Average Volume: 7.72 million shs.
  • Beta: 0.8
  • Short Ratio: 1.79

Frequently Asked Questions for Merck & Company (NYSE:MRK)

What is Merck & Company's stock symbol?

Merck & Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Company pay dividends? What is the dividend yield for Merck & Company?

Merck & Company declared a quarterly dividend on Tuesday, July 25th. Shareholders of record on Friday, September 15th will be given a dividend of $0.47 per share on Friday, October 6th. This represents a $1.88 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date of this dividend is Thursday, September 14th. View Merck & Company's Dividend History.

How were Merck & Company's earnings last quarter?

Merck & Company, Inc. (NYSE:MRK) released its quarterly earnings data on Friday, July, 28th. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.87 by $0.14. The company had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. Merck & Company had a return on equity of 26.02% and a net margin of 17.14%. The business's quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.93 earnings per share. View Merck & Company's Earnings History.

When will Merck & Company make its next earnings announcement?

Merck & Company is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for Merck & Company.

What guidance has Merck & Company issued on next quarter's earnings?

Merck & Company updated its FY17 earnings guidance on Friday, July, 28th. The company provided EPS guidance of $3.76-3.88 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.85. The company issued revenue guidance of $39.4-40.4 billion, compared to the consensus revenue estimate of $40.05 billion.

Where is Merck & Company's stock going? Where will Merck & Company's stock price be in 2017?

16 equities research analysts have issued 1-year price objectives for Merck & Company's shares. Their forecasts range from $52.00 to $80.00. On average, they expect Merck & Company's stock price to reach $70.00 in the next year. View Analyst Ratings for Merck & Company.

What are analysts saying about Merck & Company stock?

Here are some recent quotes from research analysts about Merck & Company stock:

  • 1. According to Zacks Investment Research, "Merck has made significant progress with its pipeline and is working on bringing new products to the market. New products like Keytruda and Zepatier should continue to contribute meaningfully to sales. Keytruda is gaining strong momentum from new indication of first-line lung cancer. The Keytruda development program also significantly advanced in the first half with several key regulatory approvals. Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competition in the immuno-oncology market is also a significant concern. Merck’s shares underperformed the industry this year so far. Estimates have declined slightly ahead of the company’s Q3 earnings release. Merck has a positive record of earnings surprises in the recent quarters." (10/17/2017)
  • 2. BMO Capital Markets analysts commented, "Although expectations for EPOCH were low, we were looking for an efficacy signal in mild patients, which would have increased expectations for the APECS study. Merck's press release does not provide details regarding subgroup analysis in mild patients; however, the language suggests little to no efficacy. This lowers our probability of success for APECS from 50% to 25%, Verubecestat risk-adjusted sales from ~$5Bn in 2026 to ~$2.5Bn, and our valuation from $72 to $70. However, investors should not give up on Verubecestat; APECS has a higher chance of success." (2/15/2017)
  • 3. Jefferies Group LLC analysts commented, "Our Underperform rating is predicated on under-appreciated margin pressure in the base business as well as over-optimistic expectations for Keytruda." (1/12/2017)

Are investors shorting Merck & Company?

Merck & Company saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 19,177,930 shares, an increase of 27.3% from the August 15th total of 15,062,209 shares. Based on an average daily trading volume, of 7,316,135 shares, the short-interest ratio is presently 2.6 days. Approximately 0.7% of the company's stock are sold short.

Who are some of Merck & Company's key competitors?

Who are Merck & Company's key executives?

Merck & Company's management team includes the folowing people:

  • Kenneth C. Frazier, Chairman of the Board, President, Chief Executive Officer
  • Robert M. Davis, Chief Financial Officer, Executive Vice President
  • Michael J. Holston, Executive Vice President, General Counsel
  • Mirian M. Graddick-Weir, Executive Vice President - Human Resources
  • Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
  • Richard R. DeLuca Jr., Executive Vice President, President - Merck Animal Health
  • Julie Louise Gerberding M.D., Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
  • Roger M. Perlmutter M.D. Ph.D., Executive Vice President, President - Merck Research Laboratories
  • Adam H. Schechter, Executive Vice President, President - Global Human Health
  • Rita A. Karachun, Senior Vice President Finance - Global Controller

Who owns Merck & Company stock?

Merck & Company's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Cacti Asset Management LLC (0.03%), Park National Corp OH (0.02%), Fulton Bank N.A. (0.00%), First National Bank of Mount Dora Trust Investment Services (0.00%), Bridges Investment Counsel Inc. (0.00%) and Private Asset Management Inc. (0.00%). Company insiders that own Merck & Company stock include Adam H Schechter, Adele D Ambrose, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Peter C Wendell, Rochelle B Lazarus, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Company.

Who sold Merck & Company stock? Who is selling Merck & Company stock?

Merck & Company's stock was sold by a variety of institutional investors in the last quarter, including Private Asset Management Inc., Bridges Investment Counsel Inc., Fulton Bank N.A. and Eqis Capital Management Inc.. Company insiders that have sold Merck & Company stock in the last year include Adam H Schechter, C Robert Kidder, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas R Cech and Wendell P Weeks. View Insider Buying and Selling for Merck & Company.

Who bought Merck & Company stock? Who is buying Merck & Company stock?

Merck & Company's stock was bought by a variety of institutional investors in the last quarter, including Cacti Asset Management LLC, Park National Corp OH and First National Bank of Mount Dora Trust Investment Services. View Insider Buying and Selling for Merck & Company.

How do I buy Merck & Company stock?

Shares of Merck & Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Company's stock price today?

One share of Merck & Company stock can currently be purchased for approximately $63.22.

MarketBeat Community Rating for Merck & Company (NYSE MRK)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  559 (Vote Outperform)
Underperform Votes:  555 (Vote Underperform)
Total Votes:  1,114
MarketBeat's community ratings are surveys of what our community members think about Merck & Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Merck & Company (NYSE:MRK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $70.00 (10.72% upside)
Consensus Price Target History for Merck & Company (NYSE:MRK)
Price Target History for Merck & Company (NYSE:MRK)
Analysts' Ratings History for Merck & Company (NYSE:MRK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017BMO Capital MarketsReiterated RatingOutperform$72.00N/AView Rating Details
9/5/2017Credit Suisse GroupReiterated RatingOutperform$75.00 -> $74.00LowView Rating Details
9/1/2017Cowen and CompanyReiterated RatingHold$70.00LowView Rating Details
8/20/2017Jefferies Group LLCReiterated RatingSell$52.00LowView Rating Details
8/9/2017HSBC Holdings plcUpgradeReduce -> HoldLowView Rating Details
7/29/2017Piper Jaffray CompaniesSet Price TargetBuy$70.00LowView Rating Details
7/27/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$70.00 -> $74.00MediumView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingHold$64.00 -> $66.00LowView Rating Details
7/5/2017Citigroup Inc.Set Price TargetHold$65.00LowView Rating Details
5/11/2017J P Morgan Chase & CoBoost Price TargetOverweight$74.00 -> $76.00MediumView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
2/24/2017Sanford C. BernsteinReiterated RatingMarket PerformN/AView Rating Details
1/13/2017Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
1/12/2017Morgan StanleyUpgradeEqual Weight -> Overweight$65.00 -> $71.00N/AView Rating Details
1/12/2017GuggenheimUpgradeNeutral -> Buy$61.63 -> $70.00N/AView Rating Details
10/27/2016ArgusReiterated RatingBuy$65.00 -> $80.00N/AView Rating Details
10/13/2016Bank of America CorporationUpgradeNeutral -> Buy$57.00 -> $70.00N/AView Rating Details
10/12/2016Barclays PLCReiterated RatingOverweightN/AView Rating Details
9/11/2016Berenberg BankReiterated RatingHold$62.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
2/5/2016S&P Equity ResearchReiterated RatingHold$56.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutralN/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Merck & Company (NYSE:MRK)
Earnings by Quarter for Merck & Company (NYSE:MRK)
Earnings History by Quarter for Merck & Company (NYSE MRK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2017N/AView Earnings Details
7/28/2017Q2 17$0.87$1.01$9.75 billion$9.93 billionViewN/AView Earnings Details
5/2/2017Q1 2017$0.83$0.88$9.25 billion$9.43 billionViewListenView Earnings Details
2/2/2017Q416$0.89$0.89$10.22 billion$10.10 billionViewListenView Earnings Details
10/25/2016Q316$0.99$1.07$10.17 billion$10.50 billionViewListenView Earnings Details
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.85$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.81$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merck & Company (NYSE:MRK)
2017 EPS Consensus Estimate: $3.76
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.85$0.85$0.85
Q2 20173$0.86$0.89$0.88
Q3 20172$1.01$1.01$1.01
Q4 20172$0.98$1.06$1.02
(Data provided by Zacks Investment Research)


Current Dividend Information for Merck & Company (NYSE:MRK)
Most Recent Dividend:10/6/2017
Annual Dividend:$1.88
Dividend Yield:2.97%
Dividend Growth:2.30% (3 Year Average)
Payout Ratio:76.11% (Trailing 12 Months of Earnings)
48.58% (Based on This Year's Estimates)
45.19% (Based on Next Year's Estimates)
Track Record:5 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Merck & Company (NYSE:MRK)

Dividend History by Quarter for Merck & Company (NYSE MRK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Merck & Company (NYSE:MRK)
Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 72.86%
Insider Trades by Quarter for Merck & Company (NYSE:MRK)
Institutional Ownership by Quarter for Merck & Company (NYSE:MRK)
Insider Trades by Quarter for Merck & Company (NYSE:MRK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017C Robert KidderDirectorSell5,000$63.54$317,700.00View SEC Filing  
4/3/2017Adam H SchechterEVPSell53,850$63.48$3,418,398.00View SEC Filing  
2/8/2017Patricia F RussoDirectorSell5,000$64.42$322,100.00View SEC Filing  
2/6/2017Wendell P WeeksDirectorSell5,000$64.51$322,550.00View SEC Filing  
2/3/2017Michael J HolstonEVPSell91,959$63.96$5,881,697.64View SEC Filing  
2/3/2017Thomas R CechDirectorSell5,000$63.42$317,100.00View SEC Filing  
11/10/2016Kenneth C FrazierChairmanSell140,000$65.03$9,104,200.00View SEC Filing  
11/7/2016Julie L GerberdingEVPSell85,523$60.02$5,133,090.46View SEC Filing  
11/2/2016Rochelle B LazarusDirectorSell20,000$59.06$1,181,200.00View SEC Filing  
10/3/2016Weir Mirian M GraddickInsiderSell40,800$62.07$2,532,456.00View SEC Filing  
9/1/2016Adam H SchechterEVPSell39,200$62.61$2,454,312.00View SEC Filing  
8/10/2016Clark GolestaniEVPSell3,000$63.03$189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000$61.81$24,229,520.00View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000$58.00$3,480,000.00View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000$57.99$2,609,550.00View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000$57.69$2,884,500.00View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000$57.49$1,724,700.00View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877$54.79$2,184,860.83View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040$56.11$7,352,654.40View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000$55.53$277,650.00View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313$55.08$2,055,200.04View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666$54.69$1,020,843.54View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000$54.85$274,250.00View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634$60.44$642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368$60.99$2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064$60.20$3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902$59.82$9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624$59.84$5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164$58.67$302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864$58.56$7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000$58.76$293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200$62.48$4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840$62.47$552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846$60.00$590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000$62.00$3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000$59.63$596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000$59.13$295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000$57.98$579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895$59.73$591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814$60.48$593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000$59.70$1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058$57.00$573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669$56.64$1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987$58.03$579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047$59.16$10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290$58.26$4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985$58.06$579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527$55.91$588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047$57.24$575,090.28View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225$56.43$8,195,046.75View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990$55.47$332,265.30View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870$55.04$2,414,604.80View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000$55.61$1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000$55.70$557,000.00View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520$54.52$2,263,670.40View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000$54.44$272,200.00View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000$54.68$2,734,000.00View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638$48.55$2,458,474.90View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208$46.66$1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404$46.15$249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324$44.26$2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Merck & Company (NYSE:MRK)
Latest Headlines for Merck & Company (NYSE:MRK)
DateHeadline logoFY2017 EPS Estimates for Merck & Company, Inc. (MRK) Increased by Analyst - October 17 at 8:14 AM logoMerck's Risk/Reward Is Compelling - Seeking Alpha - October 17 at 12:15 AM logoHead to Head Comparison: Forest Laboratories (FRX) versus Merck & (MRK) - October 16 at 2:10 AM logoZacks Investment Research Downgrades Merck & Company, Inc. (MRK) to Sell - October 15 at 9:36 PM logoBMO Capital Markets Reiterates Outperform Rating for Merck & Company, Inc. (MRK) - October 14 at 7:04 PM logoMerck & Co., Inc. – Value Analysis (NYSE:MRK) : October 13, 2017 - October 14 at 5:16 AM logoLost beneath headlines of five-figure drug costs — pharmaceutical price growth is weakening - October 14 at 5:16 AM logoBioAegis Therapeutics Hires Dr. Mark J. DiNubile as Chief Medical Officer to Spearhead Forthcoming Phase 2 Clinical Trials in Community-Acquired Pneumonia - October 13 at 11:25 AM logoMerck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : October 12, 2017 - October 13 at 6:59 AM logoMerck Makes $3 Million Charitable Donation to Support Swim Across America - October 13 at 6:59 AM logoMerck Will Not Seek Approval for CETP Inhibitor Anacetrapib - October 13 at 6:59 AM logo Analysts Expect Merck & Company, Inc. (MRK) Will Post Quarterly Sales of $10.44 Billion - October 13 at 4:40 AM logoMerck Provides Update on Anacetrapib Development Program - October 12 at 7:03 AM logoMerck says will not seek approval of cholesterol treatment - October 12 at 7:03 AM logoMerck Joins with the American Liver Foundation to Educate U.S. Veterans on Chronic Hepatitis C Virus (HCV) Infection - October 12 at 7:03 AM logoMerck & Company, Inc. (MRK) Given a $70.00 Price Target at BMO Capital Markets - October 11 at 6:32 PM logoSix-year Efficacy Data for GARDASIL® 9 Presented at EUROGIN 2017 Congress - October 11 at 12:30 AM logo[$$] Decoding cancer: hopes rise for a new age of precision medicine - October 11 at 12:30 AM logoMerck & Co’s (MRK) Raised to Hold - October 6 at 9:54 AM logoRoche bladder cancer drug struggles as medics focus on survival - October 6 at 4:06 AM logoMerck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Infection at The Liver Meeting® 2017 - October 5 at 8:59 AM logoMerck Highlights Ongoing Commitment to Fighting Infectious Diseases With 40 Data Presentations at ID Week 2017 - October 5 at 8:59 AM logoMerck & Co., Inc. : MRK-US: Dividend Analysis : September 15th, 2017 (record date) : By the numbers : October 4, 2017 - October 5 at 8:59 AM logoFeatured Company News - Merck to Present Latest Data on ZEPATIER for Treatment of Chronic Hepatitis C Virus Infection at The Liver Meeting 2017 - October 5 at 8:59 AM logoReviewing Merck & (MRK) & Its Peers - October 4 at 4:32 AM logoMerck Drops Two HCV Combination Programs Amid Competition - Nasdaq - October 2 at 5:34 PM logo[$$] Merck Abandons New Hepatitis C Drugs Amid Crowded Market - October 2 at 11:34 AM logo[$$] Merck Abandons New Hepatitis C Drugs Amid Crowded Market - October 2 at 11:34 AM logoMerck Drops Two HCV Combination Programs Amid Competition - October 2 at 11:34 AM logoMerck Drops Two HCV Combination Programs Amid Competition - October 2 at 11:34 AM logo[$$] LBO Profile: GHIF Uses PE Model to Tackle Global Health Challenges - October 2 at 11:34 AM logo[$$] LBO Profile: GHIF Uses PE Model to Tackle Global Health Challenges - October 2 at 11:34 AM logoMerck's Keytruda Gets FDA Nod for Advanced Gastric Cancer - September 29 at 6:26 PM logoMerck Hepatitis C exit could lift the space’s two remaining drugmakers - September 29 at 6:26 PM logoMerck Discontinues MK-3682B and MK-3682C Development Programs - September 29 at 1:24 PM logoMerck to Hold Third-Quarter 2017 Sales and Earnings Conference Call on October 27 - September 27 at 9:31 AM logoMajor Pharma Short Interest Piles On - September 27 at 9:31 AM logoOne Put, One Call Option To Know About for Merck - September 25 at 7:32 PM logoMerck's Keytruda Gets FDA Nod for Advanced Gastric Cancer - September 25 at 7:32 PM logo$10.45 Billion in Sales Expected for Merck & Company, Inc. (MRK) This Quarter - September 25 at 7:22 AM logoFDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) - September 24 at 3:58 AM logoMerck & Company, Inc. (MRK) Receives Consensus Rating of "Hold" from Brokerages - September 23 at 10:48 PM logoBetter Buy: Celgene Corporation vs. Merck & Co., Inc. - Motley Fool - September 22 at 6:06 AM logoAnalyzing Opko Health (OPK) & Merck & (MRK) - September 22 at 12:22 AM logoHead to Head Contrast: Novo Nordisk A/S (NVO) & Merck & (MRK) - September 21 at 2:14 AM logoPro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Merck, Jim Kelly and Leading Cancer Organizations To Expand Your Cancer Game Plan To Help More People Impacted by Cancer - September 20 at 6:31 AM logoOne Put, One Call Option To Know About for Merck - Nasdaq - September 18 at 11:26 PM logoMerck & Company, Inc. (MRK) Short Interest Up 27.3% in August - September 18 at 2:48 AM logoMerck & Company, Inc. (MRK) Ex-Dividend Date Scheduled for September 14, 2017 - Nasdaq - September 14 at 9:13 PM logoMerck Announces Findings from Phase 3 Study of KEYTRUDA® (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - September 13 at 6:41 AM



Merck & Company (MRK) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.